Prediction market Kalshi and public intelligence company AppliedXL have launched a pilot program allowing users to trade on the outcomes of clinical trials and Food and Drug Administration (FDA) regulatory decisions. The initiative aims to provide continuous, evidence-based market sentiment on drug development, moving beyond the nature of traditional public equities.
Trading on Clinical Trial Milestones
The collaboration introduces a series of event contracts tied to specific pharmaceutical milestones. According to a July 16 press release from the companies, initial contracts include tracking whether specific drug candidates, such as the AR1001 POLARIS-AD trial for Alzheimer’s or the FDA approval status of the Gilead/Arcellx treatment anito-cel, will meet their primary endpoints.
By creating these markets, Kalshi and AppliedXL seek to distill complex, fragmented data into a single, tradeable price. Unlike traditional stock markets, where investors must weigh the entire business at once, these contracts allow for granular exposure to the success or failure of a specific drug development program.
Data Resolution and Market Integrity
AppliedXL serves as the resolution infrastructure for these markets. CEO Francesco Marconi noted that clinical trial data is often scattered across registries and regulatory filings, frequently accompanied by corporate messaging that can obscure the underlying results. AppliedXL’s role is to reconcile these disparate data points back to primary sources to settle the contracts.
To mitigate risks associated with non-public information, the companies have implemented specific compliance measures. Kalshi CEO Tarek Mansour stated that the platform is designed to be "compliance-first," with internal rules aimed at preventing insider trading. The platform intends to surface information that is traditionally locked away, making it accessible to a broader range of participants.
Growth of the Prediction Market Sector
The launch occurs amid a broader expansion of the prediction market industry. These markets have gained traction by covering diverse categories including politics, weather, and entertainment.
Industry projections indicate significant growth for the sector. Wall Street broker Bernstein reported in April that it expects total prediction market volume to climb from $51 billion last year to $240 billion this year, with potential growth reaching $1 trillion by 2030.
Market Comparison: Equities vs. Prediction Contracts
| Feature | Traditional Equities | Clinical Prediction Markets |
|---|---|---|
| Scope of Risk | Entire company business model | Specific trial or regulatory outcome |
| Data Basis | Quarterly earnings and market sentiment | Primary source clinical/regulatory data |
| Resolution | Continuous trading until exit | Triggered by specific event outcome |
The integration of AppliedXL’s data tracking with Kalshi’s exchange infrastructure represents an attempt to formalize the use of prediction markets in high-stakes industries where information asymmetry has historically been the norm.